Author
Listed:
- Enrica Menditto
(CIRFF, Center of Pharmacoeconomics and Drug Utilization Research, Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy
These authors contributed equally.)
- Caitriona Cahir
(Data Science Centre, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
These authors contributed equally.)
- Sara Malo
(Preventive Medicine and Public Health Department, Zaragoza University, Fundación Instituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain)
- Isabel Aguilar-Palacio
(Preventive Medicine and Public Health Department, Zaragoza University, Fundación Instituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain)
- Marta Almada
(UCIBIO/REQUIMTE, Competences Centre on Active and Healthy Ageing of the University of Porto, Porto4Ageing, Faculty of Pharmacy, University of Porto, 4099-002 Porto, Portugal)
- Elisio Costa
(UCIBIO/REQUIMTE, Competences Centre on Active and Healthy Ageing of the University of Porto, Porto4Ageing, Faculty of Pharmacy, University of Porto, 4099-002 Porto, Portugal)
- Anna Giardini
(IT Department, Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia 27100, Italy)
- María Gil Peinado
(Drug Information Centre and Pharmaceutical Care Department, Muy Ilustre Colegio Oficial de Farmacéuticos de Valencia (MICOF Valencia), 46003 Valencia, Spain)
- Mireia Massot Mesquida
(Servei d’Atenció Primària Vallès Occidental, Institut Català de la Salut, 08202 Barcelona, Spain)
- Sara Mucherino
(CIRFF, Center of Pharmacoeconomics and Drug Utilization Research, Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy)
- Valentina Orlando
(CIRFF, Center of Pharmacoeconomics and Drug Utilization Research, Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy)
- Carlos Luis Parra-Calderón
(Group of Research and Innovation in Biomedical Informatics, Biomedical Engineering and Health Economy, Institute of Biomedicine of Seville, IBiS/Virgen del Rocío University Hospital/CSIC/University of Seville, 41004 Sevilla, Spain)
- Enrique Pepiol Salom
(International Committee, Muy Ilustre Colegio Oficial de Farmacéuticos de Valencia (MICOF Valencia), 46003 Valencia, Spain)
- Przemyslaw Kardas
(Medication Adherence Research Centre, Medical University of Lodz, 90-136 Lodz, Poland)
- Bernard Vrijens
(AARDEX Group & Liège University, 4000 Liège, Belgium)
Abstract
Medication adherence is a priority for health systems worldwide and is widely recognised as a key component of quality of care for disease management. Adherence-related indicators were rarely explicitly included in national health policy agendas. One barrier is the lack of standardised adherence terminology and of routine measures of adherence in clinical practice. This paper discusses the possibility of developing adherence-related performance indicators highlighting the value of measuring persistence as a robust indicator of quality of care. To standardise adherence and persistence-related terminology allowing for benchmarking of adherence strategies, the European Ascertaining Barriers for Compliance (ABC) project proposed a Taxonomy of Adherence in 2012 consisting of three components: initiation, implementation, discontinuation. Persistence, which immediately precedes discontinuation, is a key element of taxonomy, which could capture adherence chronology allowing the examination of patterns of medication-taking behaviour. Advances in eHealth and Information Communication Technology (ICT) could play a major role in providing necessary structures to develop persistence indicators. We propose measuring persistence as an informative and pragmatic measure of medication-taking behaviour. Our view is to develop quality and performance indicators of persistence, which requires investing in ICT solutions enabling healthcare providers to review complete information on patients’ medication-taking patterns, as well as clinical and health outcomes.
Suggested Citation
Enrica Menditto & Caitriona Cahir & Sara Malo & Isabel Aguilar-Palacio & Marta Almada & Elisio Costa & Anna Giardini & María Gil Peinado & Mireia Massot Mesquida & Sara Mucherino & Valentina Orlando &, 2021.
"Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance,"
IJERPH, MDPI, vol. 18(9), pages 1-9, May.
Handle:
RePEc:gam:jijerp:v:18:y:2021:i:9:p:4872-:d:548341
Download full text from publisher
References listed on IDEAS
- Aida Moreno-Juste & Beatriz Poblador-Plou & Mercedes Aza-Pascual-Salcedo & Francisca González-Rubio & Sara Malo & Julián Librero López & Victoria Pico-Soler & Eva Giménez Labrador & Sara Mucherino & V, 2020.
"Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data,"
IJERPH, MDPI, vol. 17(10), pages 1-16, May.
- Rabia Khan & Karolina Socha-Dietrich, 2018.
"Investing in medication adherence improves health outcomes and health system efficiency: Adherence to medicines for diabetes, hypertension, and hyperlipidaemia,"
OECD Health Working Papers
105, OECD Publishing.
Full references (including those not matched with items on IDEAS)
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
- Di Novi, Cinzia & Leporatti, Lucia & Levaggi, Rosella & Montefiori, Marcello, 2022.
"Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization,"
Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 1-14.
- Isabelle Rao & Adir Shaham & Amir Yavneh & Dor Kahana & Itai Ashlagi & Margaret L. Brandeau & Dan Yamin, 2020.
"Predicting and improving patient-level antibiotic adherence,"
Health Care Management Science, Springer, vol. 23(4), pages 507-519, December.
- Zhigang Guo & Lin Bai & Zhenhuan Luo & Mengyuan Fu & Liguang Zheng & Xiaodong Guan & Luwen Shi, 2021.
"Factors Associated with Free Medicine Use in Patients with Hypertension and Diabetes: A 4-Year Longitudinal Study on Full Coverage Policy for Essential Medicines in Taizhou, China,"
IJERPH, MDPI, vol. 18(22), pages 1-10, November.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:9:p:4872-:d:548341. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.